PSMB10 and acute myeloid leukemia: All these biological changes were successfully reversed by wild-type (WT) PSMB10. To further verify the function of PSMB10 in primary AML patients, we utilized PSMB10 small interfering RNA (siRNA) to reduce its expression (siPSMB10) in CD34+ BM cells (FAB, M0/M1/M2) and BM mononuclear cells (FAB, M5) isolated from AML patients, we similarly found that PSMB10 KD increased SA-β-Gal activity (Fig. 2E) and reduced the EdU+ percentage (Fig. 2F) in these primary AML cells.